OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Karen-Lise Garm Spindler
Updated on 28 January 2021
growth factor


The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.


The primary aim of this prospective study is to investigate if cfDNA in plasma is feasible and reliable for selection of mCRC patients who will benefit of anti-EGFR monoclonal antibody therapy

Secondary, to analyze developments in mutational status as reflected by cfDNA in plasma during therapy and at time of progression

Condition Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, KRAS Gene Mutation, Circulating Tumor DNA, NRAS Gene Mutation, BRAF Gene Mutation, Epidermal Growth Factor Receptor Inhibitor, egfr inhibitor, egfr blocker
Treatment Plasma circulating DNA analysis
Clinical Study IdentifierNCT03750175
SponsorKaren-Lise Garm Spindler
Last Modified on28 January 2021


Yes No Not Sure

Inclusion Criteria

Histopathologically verified metastatic colorectal cancer
Indication for systemic palliative treatment with standard Anti-EGFR monoclonal antibodies
Fit for therapy with EGFR inhibition
Consent to treatment and sampling
Measureable disease according to RECIST v 1.1
Age 18

Exclusion Criteria

PS > 2
Significant other cancer disease within 5 years of inclusion
Conditions precluding sampling during therapy and treatment breaks
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note